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After demonstrating theoretical and practical competences, parents com-
menced home monitoring. We analysed the proportion of INR within the
target range, the incidence of anticoagulant related adverse events and the
quality of life of children and parents.
Results: We included 48 children (between 2 months and 17 years old).
Eighteen patients had a mitral valve replacement and 6 an aortic valve replace-
ment. Fifteen patients had a total cavopulmonary derivation, 7 a dilated cardi-
omyopathy, 1 coronary aneurysms after Kawasaki disease and 1 an
antiphospholipid syndrome. Twenty-eight patients received anticoagulation
therapy for the first time and 20 had been treated for a long time and switched
from venipuncture to point-of-care monitor. The results of the theoretical test
of parents were excellent (average 17.3/20). Only 3 families had practical dif-
ficulties at home. 65% of INRs were within the target range. There were no
haemorrhagic and thrombosis complications. The quality of life was improved.
Conclusion: This education and training program was perfectly safe and
improved the quality of life of patients and parents. The use of similar educa-
tion program may serve to improve the outcomes of home monitoring for anti-
coagulation therapy in children.
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The aim of this retrospective study was to describe features ofinfective
endocarditis (IE) in adults with congenital heart disease (CHD).
Methods: The records of all episodes of IE diagnosed from 1974, in
patients with CHD and more than 18 years of age at diagnosis, were retrospec-
tively reviewed.
Results: Fourty-four episodes of IE occurred, 36 after 1990 (81.8%), 28 males
(63.6%). Age at diagnosis was 30.3±9years (median 28years). Ten were recurrent
episodes (22.7%). CHD was previously repared in 15 cases (34%), palliated in 7
(16%) and non-operated in 22 (50%). Dental causes were predominant (34%),
followed by cutaneous causes (25%) ; others were postoperative (4.5%), miscel-
laneous (7%) or unknown causes (29.5%). A microbial agent as identified in
95.4% of the cases : oral streptococcus and staphylococcus aureus were the
leading causative agents (respectively 41% and 36%). Left heart locations were
predominant (75%). Severe clinical cardiac complication occurred in 10 cases
(23%), an echocardiographic complication in 18 (40%). Twenty-four patients
experienced embolic events (54.5%) ; early surgical treatment was required in
25% of the cases. Three patients died due to IE (6.8%). Antibiotic prophylaxis
had been neglicted despite known risk in 41% of the cases.
Conclusion: IE is an ongoing life-threatening complication in adults with
CHD, with a significant morbidity, a high rate of prophylaxis negligence and
of recurrence.
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Introduction: Pulmonary arterial hypertension (PAH) is a devastating dis-
ease with poor survival but there are limited data describing its impact in the
paediatric population.
Objective: The objectives of this national prospective registry were to col-
lect clinical and epidemiological data and to investigate the outcome of chil-
dren with PAH.
Methods: All consecutive patients <18 years with PAH seen in 16 referral
PAH centres in France were included and evaluated after 1 and 2 years of follow-
up for WHO functional class (FC), 6-minute walk distance (6MWD) and quality
of life (QoL; CHQ-PF50 questionnaire). Persistent pulmonary hypertension of the
newborn and PAH due to congenital heart disease (CHD) were excluded.
Results: Fifty patients were included between May 2005 and June 2006. Mean
age at diagnosis was 8.7 ± 5.4 years and male/female ratio was 1/1. The preva-
lence of pediatric PAH was 4.2 cases/million. A history of prematurity, cancer and
major surgery was noticed in respectively 19%, 6% and 4% of patients. At inclu-
sion, 28% of patients were in WHO FC III or IV. Aetiology of PAH was idio-
pathic in 60%; familial in 10%, associated with but not due to CHD in 24%,
related to connective tissue disease in 4% and to portal hypertension in 2%.
Nine patients (018%) died during the 2-year follow up. Survival estimates
at 1 and 2 years were 86% and 82%. Seventy three percents of patients
improved or did not change WHO FC (n = 44). Patients remained stable
regarding 6MWD (n = 25), hemodynamics (n = 11), and QoL (n = 19). During
the 2-year follow-up, combination of PAH-specific therapies was increasingly
prescribed (44% patients vs. 22% at inclusion).
Conclusions: This first national paediatric registry showed (1) the presence
of multiple PAH aetiologies in children, that could be different from those
seen in adults, (2) the association with other co-morbidities, and (3) the stabi-
lization or even improvement in patient’s condition with the therapeutic man-
agement recommended in the current era.
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Background: TGFBR2 mutations were recently recognized among
patients with a Marfan-like phenotype and have been associated with poor car-
diovascular prognosis (early deaths, aortic dissections or early surgery for tho-
racic ascending aorta aneurysm).
Methods: Clinical features and outcomes were analysed in a group of 71
patients (including 22 children) with a TGFBR2 mutation. Patients were com-
pared with age- and gender-matched patients harbouring the FBN1 mutation
(FBN1 group n=243).
Results: The proportion of patients with aortic dilatation was similar in the
TGFBR2 group and in the FBN1 group in both adults [74 % vs. 76 %] and
children [86 %vs. 86 %] and aortic dilatation was very variable in both
TGFBR2 and FBN1 groups.
The incidence and average age of thoracic aortic surgery for aortic dissec-
tion or aortic dilatation were similar in the 2 groups (31% vs. 27% and 35±16
vs. 39±13 years, NS).
Both the frequency and the age of occurrence of aortic dissection were sim-
ilar in the TGFBR2 and the FBN1 groups for the ascending aorta [14 % vs. 10
%, p=0.26; 38±12 vs. 39±9 years, p=0.82] and for the descending aorta (3/71
vs. 8/243, p=0.72; 34±6 vs. 44±10 years, p=0.16).
